116 listed sites: Argentina (5); Canada (9); Colombia (2); Czechia (3); Estonia (2); France (22); Germany (21); Greece (6); Italy (3); Japan (4); Latvia (1); Puerto Rico (3); Romania (7); South Korea (2); Spain (6); Switzerland (10); Taiwan (2); United Kingdom (8) - 02 Sep `25Daily burden of vitiligo and other skin diseases

Daily burden of vitiligo and other skin diseases

Official title: Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)

Status: Recruiting now

Description:

AbbVie plans to enroll about 2,795 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are measuring how vitiligo and two other skin conditions affect symptoms, daily life, work, and health care use. Participants may complete exams, questionnaires, record reviews, imaging, or sample collection; no drug-related side effects are expected unless they are already receiving routine treatment. People age 12 and older may qualify. The study is recruiting at 116 listed sites across 18 countries.

Start date: September 02, 2025

Completion date: August 01, 2027

Organizer: AbbVie

Contact: Beth Rycroft

Tel.: 844-663-3742

Email: beth.rycroft@abbvie.com

Link: https://clinicaltrials.gov/study/NCT07136467

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Daily burden of vitiligo and other skin diseases . By submitting you agree to our Privacy Policy.

FAQOther Questions